Publication

Article

CURE

Winter 2013
Volume12
Issue 4

Studies Confirm Effectiveness of Colorectal Cancer Screening

Recent studies show that two common colorectal cancer screening practices are both effective.

Colorectal cancer (CRC) is often preventable, making screening for the disease essential. Recent studies show that two common screening practices are both effective.

A study published in The New England Journal of Medicine examined the effects of colonoscopy and sigmoidoscopy over 22 years of followup. Colonoscopy was associated with a two-thirds reduction in cancer risk, compared with those who did not get screened—a finding that supports existing guidelines of 10-year screening intervals for people with average risk. A separate study, published in the same journal, examined fecal occult blood testing (FOBT) during a 30-year period and found annual screening reduced the risk of dying from CRC by about a third, compared with individuals who were not screened using this method. Even patients taking the test once every two years lowered the risk of dying from CRC by 22 percent, compared with those not screened.

The results of these studies show that each method is effective but do not prove that one method is better than the other—that would require a head-to-head study. Two large randomized studies, one in the U.S. and another in Spain, are underway to compare CRC screening techniques.

While colonoscopy screening is more well-known, FOBT is less invasive and, initially, less costly, requiring stool samples to check for blood. An FOBT that reveals blood will need a colonoscopy follow-up to confirm and remove potential pre-cancerous polyps.

Related Videos
Image of Dr. Fakih.
Image of Doctor with blonde hair.
Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.
Dr. Debu Tripathy is a professor and chairman of the Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, in Houston, and the editor-in-chief of CURE®.
Dr. Suneel Kamath is an assistant professor of medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, in Ohio.
Image of Dr. Scott Kopetz
Dr. Azka Ali is a medical oncologist at the Cleveland Clinic Taussig Cancer Institute, in Ohio.
Dr. Maxwell Lloyd, a Clinical Fellow in Medicine in the Department of Medicine at Beth Israel Deaconess Medical Center in Boston.
Dr. Maxwell Lloyd, a Clinical Fellow in Medicine, in the Department of Medicine, at Beth Israel Deaconess Medical Center in Boston.
Dr. Aditya Bardia is a professor in the Department of Medicine, Division of Hematology/Oncology, director of Translational Research Integration, and a member Signal Transduction and Therapeutics, at University of California, Los Angeles (UCLA) Health Jonsson Comprehensive Cancer Center.
Related Content